US EditionPublished • loading... • Updated
Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
The daily pill cut the risk of death by 60% and raised median survival to 13.2 months, RevMed said.
- Revolution Medicines announced Monday that its experimental pill reduced the risk of death by 60% in a Phase 3 Pancreatic cancer trial, with RevMed CEO Mark Goldsmith calling the results "dramatic, practice-changing outcomes."
- RAS mutations found in more than 90% of Pancreatic cancer cases drive tumor growth, which the pill targets as an alternative to cytotoxic intravenous chemotherapy, the standard treatment.
- Patients taking the pill lived 13.2 months versus 6.7 months on chemotherapy, an increase of 6.5 months, with Goldsmith noting no drug has previously shown such an overall survival benefit in a Phase 3 pancreatic trial.
- The company plans to seek Food and Drug Administration approval using a National Priority Voucher that expedites review, and Shares jumped more than 30% following Monday's announcement.
- Despite media reports identifying the company as a potential acquisition target, Revolution Medicines is conducting a Phase 3 trial for newly diagnosed patients to expand the pill's reach.
Insights by Ground AI
21 Articles
21 Articles
Pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines ’ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all primary and secondary endpoints in a trial of people whose cancer...
Coverage Details
Total News Sources21
Leaning Left4Leaning Right1Center12Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 23%
C 71%
Factuality
To view factuality data please Upgrade to Premium
